Galmed Pharmaceuticals (GLMD) Long-Term Investments (2017 - 2025)

Galmed Pharmaceuticals' Long-Term Investments history runs 9 years deep, the most recent figure standing at $1.6 million for Q3 2025.

• In Q3 2025, Long-Term Investments fell 51.21% year-over-year to $1.6 million; the TTM figure through Sep 2025 stood at $1.6 million (down 51.21% YoY), while the FY2024 annual figure was $2.1 million, down 35.1% from the prior year.
• Long-Term Investments was $1.6 million for Q3 2025 at Galmed Pharmaceuticals, roughly flat from $1.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $13.4 million in Q3 2021 to a low of -$10.0 million in Q1 2021.
• Historically, Long-Term Investments has averaged $860625.0 across 5 years, with a median of $2.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments sank 101.91% in 2022, then surged 1380.39% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $13.4 million in 2021, then tumbled by 88.77% to $1.5 million in 2022, then surged by 117.67% to $3.3 million in 2023, then sank by 35.1% to $2.1 million in 2024, then declined by 24.82% to $1.6 million in 2025.
• The last three Long-Term Investments figures came in at $1.6 million (Q3 2025), $1.6 million (Q2 2025), and $2.1 million (Q1 2025), per Business Quant data.